Andere talen Corvus Pharmaceuticals, Inc.

Aandelen

CRVS

US2210151005

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 29-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,58 ^USD	+8,97%		+9,72%	-10,23%

09/04	Corvus Pharmaceuticals, Inc. Kondigt de start aan van een placebogecontroleerde Fase 1 klinische studie met soquelitinib voor atopische dermatitis	CI
21/03	CORVUS PHARMACEUTICALS, INC. : Oppenheimer nog altijd een koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09/04
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20/03
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	19/03
Corvus: Q4 Earnings Snapshot	19/03
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19/03
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13/03
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12/02
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09/02
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	09/02
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	09/02
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	08/02
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	08/02
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	06/02
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	23/01
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	23/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Corvus Pharmaceuticals, Inc.

Aandelen

CRVS

US2210151005

Andere talen

Filters